Pluristem to Present at Oppenheimer 23rd Annual Healthcare Conference
December 12 2012 - 3:00AM
Pluristem Therapeutics, Inc. (Nasdaq:PSTI)
(TASE:PLTR) today announced that William R. Prather RPh, MD, Senior
VP Corporate Development, will present at the Oppenheimer 23rd
Annual Healthcare Conference at the Waldorf Astoria in New York
City. Dr. Prather's presentation on Wednesday, December 12th at
2:45PM will focus on the Company's hematology program.
Pluristem recently announced it has assembled a prestigious
group of world renowned hematologists to form a new Clinical
Advisory Board (CAB) in hematology. The CAB is assisting the
Company in determining the most appropriate hematological
indications for Pluristem's PLacental eXpanded (PLX) cells. The
Company's goal is to pursue those indications that can move through
regulatory approvals fastest, in order to provide the greatest
therapeutic benefit to patients in need.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a
leading developer of placenta-based cell therapies. The Company's
patented PLX (PLacental eXpanded) cells are a drug delivery
platform that releases a cocktail of therapeutic proteins in
response to a host of local and systemic inflammatory and ischemic
diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product
that requires no tissue matching prior to administration. Pluristem
is focusing on the development of PLX cells administered locally to
potentially treat systemic diseases and potentially obviating the
need to use the intravenous route.
Pluristem has a strong patent and patent applications portfolio,
company-owned GMP certified manufacturing and research facilities,
strategic relationships with major research institutions and a
seasoned management team. For more information visit
www.pluristem.com, the content of which is not part of this press
release.
The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities
laws. For example, when we discuss our goal to pursue hematological
indications in order to provide the greatest therapeutic benefit to
patients in need, we are using forward-looking statements. These
forward-looking statements are based on the current expectations of
the management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; we may
encounter delays or obstacles in launching and/or successfully
completing our clinical trials; our products may not be approved by
regulatory agencies, our technology may not be validated as we
progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; our products may wind up being more expensive than we
anticipate; results in the laboratory may not translate to equally
good results in real surgical settings; results of preclinical
studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm
recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of
market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of Pluristem to
differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Pluristem, reference is made to Pluristem's
reports filed from time to time with the Securities and Exchange
Commission.
CONTACT: Pluristem Therapeutics Inc.:
William Prather R.Ph., M.D. Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Sep 2023 to Sep 2024